Kymera Q4 net loss $14.4M, cash $745M; KT-474 Phase 2 data due H1 2025

Kymera Therapeutics, Inc.

2023-FY EPS reported -$2.52 revenue$78,592,000

Net loss $14.4M in Q4, $147.0M for FY2023; collaboration revenue $47.9M Q4, $78.6M FY.
Cash and investments $745M as of Jan 9, 2024, including $301M from equity offering; runway into H1 2027.
KT-474 Phase 2 trials in HS and AD started; topline data expected H1 2025; $55M milestone from Sanofi.
KT-621 STAT6 degrader Phase 1 expected H2 2024; KT-294 TYK2 Phase 1 expected H1 2025; data in 2025.
Additional Phase 1 data for KT-333 (STAT3) and KT-253 (MDM2) expected in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Kymera Therapeutics, Inc. reported financial results for the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023.

Period: the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 22, 2024, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-018413

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.